Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis

Carlos R. Bachier, MD, Sanjay K. Aggarwal, MD, Kalin Hennegan, MPH, Andrew Milgroom, Kevin Francis, Marcello Rotta, MD

Blood (2019) 134 (Supplement_1): 2109.

https://doi.org/10.1182/blood-2019-130563

Published: 2019

Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 2868.

https://doi.org/10.1182/blood-2019-127566

Published: 2019

Journal Articles

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Madan Jagasia, MBBS, MS, MMHC, Amandeep Salhotra, MD, Carlos R. Bachier, MD, Behyar Zoghi, MD, PhD, FACP, Aleksandr Lazaryan, MDPhDMPH, Daniel J. Weisdorf, MD, James Essell, MD, Laurie S. Green, MD, Olivier Schueller, PhD, Lindy Huang, Zhongming Yang, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2019) 134 (Supplement_1): 872.

https://doi.org/10.1182/blood-2019-125986

Published: 2019

Journal Articles

Role of G-CSF after High-Dose Post-Transplantation Cyclophospamide

Mohammed M Elayan, PharmD, Carlos R. Bachier, MD, Minoo Battiwalla, MD, Darby Siler, PharmD

Blood (2018) 132 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2018-99-112256

Published: 2018

Journal Articles

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Madan Jagasia, MD MS, Amandeep Salhotra, MD, Carlos R. Bachier, MD, James Essell, MD, Daniel J. Weisdorf, MD, Behyar Zoghi, MD PhD, Laurie S. Green, MD, Olivier Schueller, PhD, Alexandra Zanin-Zhorov, PhD, Jonathan M. Weiss, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2018) 132 (Supplement 1): 602.

https://doi.org/10.1182/blood-2018-99-111896

Published: 2018

Journal Articles

Open-Label Study to Determine the Feasibility of Ixazomib As Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma

Carlos R Bachier, MD, Paul J Shaughnessy, MD, Jeffrey V Matous, MD, Jesus G. Berdeja, MD

Blood (2017) 130 (Supplement 1): 5537.

https://doi.org/10.1182/blood.V130.Suppl_1.5537.5537

Published: 2017

Journal Articles

Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor Is an Alternative to Donor Lymphocyte Infusion for Relapse after Allogeneic Stem Cell Transplantation and Is Associated with Increase Immune Effector Cells and Polarization to Type 2 Dendritic Cells.

Carlos R. Bachier, MD, Paul Shaughnessy, MD, Brad Smith2, PhD, Richard Salinas, Charles F. LeMaistre, MD

Blood (2007) 110 (11): 1647.

https://doi.org/10.1182/blood.V110.11.1647.1647

Published: 2007

NARROW

Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Role of G-CSF after High-Dose Post-Transplantation Cyclophospamide

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Open-Label Study to Determine the Feasibility of Ixazomib As Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma

Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor Is an Alternative to Donor Lymphocyte Infusion for Relapse after Allogeneic Stem Cell Transplantation and Is Associated with Increase Immune Effector Cells and Polarization to Type 2 Dendritic Cells.

Email alerts

ASH Publications

American Society of Hematology

Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Role of G-CSF after High-Dose Post-Transplantation Cyclophospamide

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Open-Label Study to Determine the Feasibility of Ixazomib As Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma

Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor Is an Alternative to Donor Lymphocyte Infusion for Relapse after Allogeneic Stem Cell Transplantation and Is Associated with Increase Immune Effector Cells and Polarization to Type 2 Dendritic Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only